This session will review the relationship and underlying mechanisms between obesity and cardiovascular disease with attention to the individual variability between BMI and CV risk.
|
The body mass index (BMI) is the most commonly used screening tool for obesity. However, the BMI is a population-based tool with several limitations when applied to individuals.
|
This session will examine the use of on-label anti-obesity pharmacotherapy to treat obesity.
|
Join Dr. Carolynn Francavilla and Stephanie Burke, both level 1 CrossFit Coaches, in this session where we look past BMI and see the inner athlete in everyone.
|
Obesity with sarcopenia poses a dual health concern especially in aging populations.
|
We are at a unique place in obesity care history where anti-obesity medications (AOMs) are showing promising, clinically significant weight loss for persons with obesity.
|
Social determinants of health, the conditions in the environments where people are born, live, learn, work, play, worship, and age, play a large role in how well patients can adhere to weight manag
|
In this session, Liz Paul will describe her experiences living with obesity, including her journey to overcoming internalized weight bias.
|
OMA Clinical Practice Statement Updates - Harold Bays, MD, FOMA, Lydia Alexander, MD, FOMA, Karlijn Burridge, PA-C, Suzanne Cuda, MDCME/CE Expiration Date: 3/19/25
|
Insulin resistance (IR) is a common biochemical abnormality in patients with excess adiposity, obesity, and its complications.
|